Epizyme, Inc. (EPZM) Stake Boosted by NEA Management Company LLC

NEA Management Company LLC raised its holdings in shares of Epizyme, Inc. (NASDAQ:EPZM) by 3.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,460,851 shares of the biopharmaceutical company’s stock after buying an additional 200,000 shares during the quarter. Epizyme comprises about 4.3% of NEA Management Company LLC’s holdings, making the stock its 3rd largest position. NEA Management Company LLC owned 9.33% of Epizyme worth $123,079,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the stock. Dimensional Fund Advisors LP lifted its stake in Epizyme by 61.4% during the first quarter. Dimensional Fund Advisors LP now owns 65,194 shares of the biopharmaceutical company’s stock worth $1,118,000 after purchasing an additional 24,807 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its stake in Epizyme by 25.3% during the first quarter. Schwab Charles Investment Management Inc. now owns 161,646 shares of the biopharmaceutical company’s stock worth $2,773,000 after purchasing an additional 32,650 shares during the last quarter. Federated Investors Inc. PA lifted its stake in Epizyme by 477.6% during the second quarter. Federated Investors Inc. PA now owns 89,505 shares of the biopharmaceutical company’s stock worth $1,352,000 after purchasing an additional 74,009 shares during the last quarter. American International Group Inc. lifted its stake in Epizyme by 7.1% during the first quarter. American International Group Inc. now owns 24,779 shares of the biopharmaceutical company’s stock worth $425,000 after purchasing an additional 1,638 shares during the last quarter. Finally, Woodstock Corp lifted its stake in Epizyme by 5.5% during the second quarter. Woodstock Corp now owns 37,078 shares of the biopharmaceutical company’s stock worth $560,000 after purchasing an additional 1,945 shares during the last quarter. Institutional investors and hedge funds own 70.95% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://stocknewstimes.com/2017/11/18/nea-management-company-llc-grows-position-in-epizyme-inc-epzm.html.

Several equities research analysts have issued reports on EPZM shares. BidaskClub lowered Epizyme from a “sell” rating to a “strong sell” rating in a research note on Friday, July 28th. Royal Bank Of Canada set a $20.00 target price on Epizyme and gave the company a “buy” rating in a research note on Saturday, August 5th. HC Wainwright reissued a “buy” rating on shares of Epizyme in a research note on Monday, August 7th. Leerink Swann reissued an “outperform” rating and issued a $28.00 target price (down previously from $31.00) on shares of Epizyme in a research note on Wednesday, August 9th. Finally, Cann reissued a “buy” rating and issued a $26.00 target price on shares of Epizyme in a research note on Tuesday, September 19th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $22.67.

In related news, Director David M. Mott purchased 200,000 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The shares were bought at an average price of $15.25 per share, for a total transaction of $3,050,000.00. Following the purchase, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $91,500. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $15.68, for a total value of $235,200.00. Following the completion of the transaction, the insider now directly owns 22,228 shares in the company, valued at $348,535.04. The disclosure for this sale can be found here. Insiders sold a total of 45,000 shares of company stock worth $733,950 in the last 90 days. 25.20% of the stock is currently owned by company insiders.

Epizyme, Inc. (EPZM) traded down $0.25 during mid-day trading on Friday, hitting $12.65. The company’s stock had a trading volume of 223,975 shares, compared to its average volume of 581,868. Epizyme, Inc. has a 1 year low of $9.30 and a 1 year high of $20.45.

Epizyme (NASDAQ:EPZM) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.02. sell-side analysts expect that Epizyme, Inc. will post -2.23 earnings per share for the current fiscal year.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply